Mark A. Subler
Impact in
- Oncology top 1%
- Cancer-related Molecular Pathways
- Bone health and treatments
- Biotechnology top 2%
- Cancer Research and Treatments
Papers in
-
- Circular RNAs in diseases 5
- Fibroblast Growth Factor Research 4
- Bone Metabolism and Diseases 4
- Oncology 29
- Cancer-related Molecular Pathways 19
- Bone health and treatments 9
- Co-authors
- Sumitra Deb (12 shared papers)Daniel W. Martin (7 shared papers)Jolene J. Windle (45 shared papers)Raquel Muñoz (5 shared papers)Daniel H. Conrad (4 shared papers)Doris Brown (5 shared papers)Mohamed Rahmani (3 shared papers)Steven Grant (3 shared papers)
- Journals
- Molecular and Cellular Biology (7 papers)Cancer Research (7 papers)Journal of Bone and Mineral Research (5 papers)Hepatology (4 papers)Oncotarget (3 papers)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Mark A. Subler
65 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 92
- Oncology 1.4k
- Biotechnology 261
- Molecular Biology 1.9k
- Cancer Research 369
- Pathology and Forensic Medicine 308
Countries citing papers authored by Mark A. Subler
This map shows the geographic impact of Mark A. Subler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Subler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Subler more than expected).
Fields of papers citing papers by Mark A. Subler
This network shows the impact of papers produced by Mark A. Subler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Subler. The network helps show where Mark A. Subler may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Subler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 219 | |
| 2 | 1992 | 161 | |
| 3 | 1996 | 153 | |
| 4 | 1998 | 146 | |
| 5 | 1992 | 144 | |
| 6 | 2008 | 130 | |
| 7 | 1987 | 128 | |
| 8 | Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. | 2003 | 110 |
| 9 | 1993 | 96 | |
| 10 | 2006 | 90 | |
| 11 | 1987 | 87 | |
| 12 | Wild-type human p53 activates the human epidermal growth factor receptor promoter. | 1994 | 86 |
| 13 | 1997 | 80 | |
| 14 | 2006 | 77 | |
| 15 | 1998 | 73 | |
| 16 | 2008 | 68 | |
| 17 | 2012 | 67 | |
| 18 | 2003 | 59 | |
| 19 | 2017 | 52 | |
| 20 | 2017 | 51 |
About Mark A. Subler
Mark A. Subler is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Immunology and Genetics, having authored 65 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (19 papers), Cancer Mechanisms and Therapy (14 papers), Bone health and treatments (9 papers), Cancer Research and Treatments (8 papers), Virus-based gene therapy research (7 papers), Circular RNAs in diseases (5 papers), Fibroblast Growth Factor Research (4 papers) and Bone Metabolism and Diseases (4 papers). The work is most often cited by research in Oncology (1.4k citations), Biotechnology (261 citations), Molecular Biology (1.9k citations), Cancer Research (369 citations) and Pathology and Forensic Medicine (308 citations). Mark A. Subler has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Sumitra Deb, Daniel W. Martin, Jolene J. Windle, Raquel Muñoz, Daniel H. Conrad, Doris Brown, Mohamed Rahmani, Steven Grant, Paul Dent and Chunrong Yu. Their work appears in journals such as Molecular and Cellular Biology, Cancer Research, Journal of Bone and Mineral Research, Hepatology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.